Browse the evidence

Metabolic dysfunction-associated steatohepatitis is now a leading indication for liver transplantation.

Healthcare providers should consider MASLD as a critical factor in liver transplant evaluations.

The quality of existing clinical evidence from anti-obesity trials generally ranges from low to moderate.

Practitioners should be cautious in interpreting the effectiveness of current anti-obesity medications due to the low to moderate quality of evidence.

Most trials suffered from publication bias.

Practitioners should be aware of potential biases in the published literature on anti-obesity drugs.

Additional higher-quality clinical trials are needed to gain more confidence in the estimate of the effect of currently used anti-obesity medicines.

Practitioners should advocate for and support the conduct of higher-quality trials to improve treatment options for obesity.

Ongoing research is crucial to confirm the long-term safety, effectiveness, and clinical role of these agents.

Practitioners should stay updated on research developments regarding these oral agents.

None of the four glucagon-like peptide-1 receptor agonist (GLP-1RA) or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA therapies were cost-effective compared with lifestyle management.

Practitioners should consider lifestyle management as the most cost-effective option for treating obesity in this population.

No clinically relevant differences in generic health-related quality of life (HRQoL) were observed between sleeve gastrectomy and Roux-en-Y gastric bypass.

Clinicians can expect similar HRQoL outcomes from both surgical options for patients with severe obesity.

Perioperative mortality for bariatric surgery averages 0.3% in accredited centers.

Practitioners can reassure patients about the low perioperative mortality risk in accredited facilities.

Change in accelerometry-measured MVPA at 1 year and self-reported change in PA at 1 and 4 years were not associated with CVD outcomes.

Self-reported PA changes may not be reliable indicators of CVD risk in this population.

The food industry generates close to $2 trillion in annual sales in the United States.

This indicates the significant economic impact of the food industry.

Food politics refers to how governments make decisions affecting food systems.

Understanding food politics is crucial for navigating food policy and industry dynamics.

Power over food production and consumption is distributed unequally, favoring large corporations.

This suggests that advocacy for equitable food policies is necessary.

Cardiovascular autonomic neuropathy (CAN) is not significantly associated with mortality in men with type 2 diabetes.

Men with type 2 diabetes may require different monitoring strategies for mortality risk compared to women.

There was no association found between weight loss and improvement in FEV1 or FVC.

Weight loss from GLP-1 therapies may not lead to improvements in lung function, indicating the need for further investigation.

Side effects were common and led to discontinuation of the medication in 18.5% of patients.

Clinicians should monitor for side effects in patients on GLP-1 therapies, as they may affect treatment adherence.

The annual additional direct medical cost for Semaglutide was USD 4,086.82.

Practitioners should consider the high cost of Semaglutide when discussing treatment options.

Semaglutide would be cost-effective at a threshold of $120,000 per QALY gained if the annual cost were lowered by 18% to $7,055.

Reducing the cost of semaglutide could enhance its affordability and accessibility for patients.

Semaglutide is projected to increase annual health care spending by $23 billion.

Healthcare systems should prepare for increased spending associated with the adoption of semaglutide.

The healthcare situation for people with obesity in Germany is deficient.

Healthcare providers should recognize the deficiencies in the current obesity care system.

There were previously no legal frameworks for guideline-based care for people with obesity.

Legislators need to establish legal frameworks to support guideline-based obesity care.

41.9% of the US population is classified as obese.

Practitioners should be aware of the significant prevalence of obesity in the population.

There was no significant effect of the intervention on daily steps, daily activity energy expenditure, or moderate-to-vigorous physical activity compared to the control group.

Practitioners should note that the program did not significantly increase physical activity levels.

There were no differences in anthropometric variables after the intervention period with strength training.

Strength training may not lead to changes in body composition metrics in this population.

Infertility affects up to 17.5% of the global population.

Awareness of the prevalence of infertility can guide public health initiatives.